These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33682120)

  • 1. Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies.
    Youn B; Wilson IB; Mor V; Trikalinos NA; Dahabreh IJ
    Health Serv Res; 2021 Jun; 56(3):486-496. PubMed ID: 33682120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011).
    Bradley CJ; Yabroff KR; Mariotto AB; Zeruto C; Tran Q; Warren JL
    J Clin Oncol; 2017 Feb; 35(5):529-535. PubMed ID: 28045621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated With Use of High-Cost Agents for the Treatment of Metastatic Non-Small Cell Lung Cancer.
    Bradley CJ; Eguchi M; Perraillon MC
    J Natl Cancer Inst; 2020 Aug; 112(8):802-809. PubMed ID: 31710664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater Spending Associated with Improved Survival for Some Cancers in OCM-Defined Episodes.
    Baumgardner J; Shahabi A; Linthicum M; Vine S; Zacker C; Lakdawalla D
    J Manag Care Spec Pharm; 2018 Jun; 24(6):504-513. PubMed ID: 29799330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death.
    Chen CT; Li L; Brooks G; Hassett M; Schrag D
    Health Serv Res; 2018 Aug; 53(4):2118-2132. PubMed ID: 28748564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.
    Kehl KL; Hassett MJ; Schrag D
    Cancer Med; 2020 Mar; 9(6):2019-2029. PubMed ID: 31989786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.
    Owonikoko TK; Ragin C; Chen Z; Kim S; Behera M; Brandes JC; Saba NF; Pentz R; Ramalingam SS; Khuri FR
    Oncologist; 2013; 18(5):600-10. PubMed ID: 23635558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Gray SW; Chen AB; Weeks JC; Schrag D
    JAMA; 2012 Apr; 307(15):1593-601. PubMed ID: 22511687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional variation in spending and survival for older adults with advanced cancer.
    Brooks GA; Li L; Sharma DB; Weeks JC; Hassett MJ; Yabroff KR; Schrag D
    J Natl Cancer Inst; 2013 May; 105(9):634-42. PubMed ID: 23482657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital Variation in Spending for Lung Cancer Resection in Medicare Beneficiaries.
    Jean RA; Bongiovanni T; Soulos PR; Chiu AS; Herrin J; Kim N; Xu X; Kim AW; Gross CP
    Ann Thorac Surg; 2019 Dec; 108(6):1710-1716. PubMed ID: 31400321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
    Kwan SW; Mortell KE; Hippe DS; Brunner MC
    J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
    Criss SD; Palazzo L; Watson TR; Paquette AM; Sigel K; Wisnivesky J; Kong CY
    PLoS One; 2020; 15(1):e0228288. PubMed ID: 31995619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.
    Stewart M; Norden AD; Dreyer N; Henk HJ; Abernethy AP; Chrischilles E; Kushi L; Mansfield AS; Khozin S; Sharon E; Arunajadai S; Carnahan R; Christian JB; Miksad RA; Sakoda LC; Torres AZ; Valice E; Allen J
    JCO Clin Cancer Inform; 2019 Jul; 3():1-15. PubMed ID: 31335166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients.
    Gilden DM; Kubisiak JM; Pohl GM; Ball DE; Gilden DE; John WJ; Wetmore S; Winfree KB
    J Med Econ; 2017 Feb; 20(2):151-161. PubMed ID: 27574722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Hospice on Spending and Utilization Among Patients With Lung Cancer in Medicare.
    Kalidindi Y; Segel J; Jung J
    Am J Hosp Palliat Care; 2020 Apr; 37(4):286-293. PubMed ID: 31564110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.